SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense volatility, with the community actively debating whether the token is primed for a massive short squeeze or trapped in a persistent pump-and-dump cycle. Retail traders remain deeply divided, with some aggressively loading up on dips while others express concerns over potential manipulation and a lack of official communication.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is currently attracting significant attention due to its pending merger with Agility Robotics, a move that has sparked intense debate among community members regarding its long-term potential versus concerns of a pump-and-dump scheme. Investors are actively discussing the company's backing by major technology and industrial giants, weighing the risks of SPAC-related volatility against the speculative appeal of the emerging humanoid robotics sector.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. is trending as investors debate the company's progress in establishing domestic rare earth magnet processing capabilities to bypass Chinese supply chains, a move central to upcoming defense sourcing mandates. While some community members highlight the potential for long-term growth driven by federal procurement policy and strategic infrastructure investments, others express caution regarding potential market manipulation and the execution risks associated with scaling operations.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as investors focus on its role in the AI-agent infrastructure space, with many in the community highlighting the protocol's chain abstraction and recent developments in privacy-preserving technology. While some traders are capitalizing on high volatility with short-term strategies, long-term holders remain active, weighing the potential for utility-driven growth against broader market corrections.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock shares faced a sharp sell-off as the asset manager capped withdrawals from its private credit fund following redemption requests that exceeded the quarterly limit. The community is actively debating the health of the broader private credit sector, with investors drawing comparisons to past liquidity crises while others monitor potential contagion risks across alternative asset managers.

Bullish engages in the management of a digital asset platform. It also offers market infrastructure and information services. The company was founded by Brendan Francis Blumer in 2020 and is headquartered in George Town, Cayman Islands.

Bullish

Bullish is trending as investors weigh its aggressive expansion, including the acquisition of Equiniti, against significant volatility in crypto markets and mixed earnings reports. The community remains deeply divided, with some investors betting on the stock as a long-term infrastructure play backed by institutional accumulation, while critics express frustration over the stock's persistent downward trend since its IPO.

Jabil, Inc. engages in the provision of manufacturing services and solutions. It operates through the Electronics Manufacturing Services (EMS) and Diversified Manufacturing Services (DMS) segments. The EMS segment focuses on leveraging information technology, supply chain design and engineering, technologies largely centered on core electronics, utilizing a large-scale manufacturing infrastructure, and the ability to serve a broad range of end markets. The DMS segment offers engineering solutions with an emphasis on material sciences, machining, tooling, and molding of engineered plastic and metal parts. The company was founded by William E. Morean and James Golden in 1966 and is headquartered in St. Petersburg, FL.

Jabil Inc

Jabil Inc. is trending as investors digest strong fiscal quarterly results that topped expectations and a new billion-dollar share repurchase authorization. The stock is drawing significant attention from the community due to its pivotal role as a hardware backbone for AI data center infrastructure and cloud expansion, keeping sentiment bullish as the company navigates stabilizing demand across its diverse end-markets.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors rotate into defensive healthcare stocks, further fueled by highly positive phase 3 data for its obesity drug retatrutide. The community is actively discussing the company's aggressive acquisition strategy, its competitive lead in the GLP-1 sector, and the potential for long-term growth as capital shifts away from high-beta technology shares.

Oatly Group AB is a holding company, which focuses on developing expertise around oats, a global power crop with inherent properties suited for sustainability and human health. It operates through the following geographical segments: Europe & International, North America and Greater China. The company was founded by Björn Öste in 1994 and is headquartered in Malmö, Sweden.

Oatly Group AB - ADR

Oatly Group

Oatly is currently a major focus for investors as the community eagerly awaits a potential China carve-out to stabilize the balance sheet and bolster liquidity. Despite concerns over debt and share price performance, there is significant enthusiasm surrounding the company's expansion into new product categories like matcha and cold foam, which many hope will drive the next wave of profitable growth.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending as investors weigh strong earnings growth and a robust shift toward value-added services against regulatory pressure from proposed credit card interest rate caps and interchange fee legislation. While some in the community see the current volatility as a discount opportunity for a resilient compounder, others remain cautious due to ongoing institutional uncertainty and debates over the long-term impact of AI-driven payment solutions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?

J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.

JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?

J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.

J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?

JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.

J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.

J&J's Pipeline Progress & New Drugs Promise Stronger Long-Term Growth 

J&J's expanding pipeline, new drug approvals and rising sales from cancer medicines are expected to fuel growth.

Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Wedbush Analyst Says

Wedbush upped their target price on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an 'outperform' rating in a research report on Wednesday...

Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPS

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.70. The company had revenue of $56.37 million for the quarter, compared to...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from Analysts

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has received an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a ho...

331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC

Jennison Associates LLC bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 331,164 shares of the company's stock, v...

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PTGXProtagonist Therapeutics Inc

Latest PTGX News